Clinical Trial Update: Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sequential vaccination with 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in all…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease Prevention in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)
• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2014-04-21